Clinical Trial Update: EVARREST™ Fibrin Sealant Patch Post-Market Study [Phase 4]

View source ↗

Summary

Post-market Phase 4 trial update for EVARREST fibrin sealant patch evaluating hemorrhage and soft tissue bleeding outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hemorrhage
• Soft Tissue Bleeding

Drugs mentioned

• EVARREST (fibrin sealant patch)

Snippet

Sponsor: Ethicon, Inc. | Conditions: Hemorrhage, Soft Tissue Bleeding | Phase 4 | Status: COMPLETED | Results posted: 2018-01-17